Daily ReportOct 1, 2026
Sepsis, October 1 edition
We read 38 papers and selected 3.
Summary
Today’s most impactful sepsis studies span mechanistic therapeutics, neonatal molecular diagnosis, and antibiotic dosing in critically ill patients. Particularly notable are the identification of platelet mevalonate metabolism as a target for septic thrombosis, the improved detection of adverse outcomes using umbilical-cord qPCR in preterm infants, and the negative randomized-trial finding that meropenem infusion strategy did not improve outcomes across renal-function subgroups.
Research Themes
- Mechanistic targeting of septic thrombosis
- Molecular diagnosis and prognostication of neonatal sepsis
- Evidence-based optimization of meropenem administration
Selected Articles
1. Mevalonate Metabolism Orchestrates Platelet Hyperactivation via Protein Prenylation to Aggravate Septic Thrombosis.
This translational mechanistic study demonstrated that the platelet mevalonate pathway is activated during sepsis and promotes platelet hyperactivation through protein prenylation, including enhanced Rap1-Talin-1 interaction. Platelet-specific mevalonate kinase deficiency and the prenyl diphosphate synthase inhibitors TH-Z145 and TH-Z93 reduced platelet activation, neutrophil extracellular trap formation, septic thrombosis, and mortality in mice.
Impact: The study identifies a previously underappreciated metabolic mechanism connecting infection to platelet-driven microvascular thrombosis and provides pharmacologic proof-of-concept for targeting this pathway. It is important because it could open a treatment strategy distinct from broad immunosuppression or conventional anticoagulation.
Clinical Implications: The findings support further development of mevalonate-pathway or prenylation inhibitors for septic thrombosis, but they do not justify clinical use because efficacy and safety have only been demonstrated in experimental models. Future translation must address bleeding risk, immune effects, infection clearance, and optimal treatment timing.
Key Findings
- The mevalonate pathway was highly activated in platelets during infection.
- Platelet-specific mevalonate kinase deficiency reduced platelet activation, neutrophil extracellular trap formation, and sepsis-induced intravascular thrombosis.
- TH-Z145 and TH-Z93 reduced platelet activation and septic thrombosis and prolonged survival in septic mice.
- Rap1 prenylation and Rap1-Talin-1 interaction were implicated as downstream mechanisms.
Methodological Strengths
- The study combined a platelet-specific genetic model with pharmacologic intervention and mechanistic protein-interaction analyses.
- It linked molecular metabolism to cellular phenotypes, thrombosis, and survival outcomes in vivo.
Limitations
- The evidence is based on experimental sepsis models, and the number and characteristics of animals are not provided in the abstract.
- The translational safety profile, including bleeding and effects on host defense, remains unresolved.
Future Directions: Independent validation in multiple sepsis models, dose-ranging and pharmacokinetic studies, assessment of bleeding and antimicrobial-host-defense effects, and eventual early-phase clinical trials are needed. Biomarkers of platelet mevalonate-pathway activation could help identify patients most likely to benefit.
Sepsis is a life-threatening systemic inflammatory disorder that triggers disseminated intravascular coagulation and microthrombosis, in which exaggerated platelet activation exacerbates disease progression. The mevalonate pathway is responsible for the biosynthesis of vital isoprenoids and sterols, also playing an important role in the prenylation modification of proteins. We found the mevalonate metabolic pathway is highly activated in platelets during infection. The interruption of this pathway, using platelet specific mevalonate kinase deficiency mice model, could significantly suppress platelet activation and NETosis, alleviating sepsis-induced intravascular thrombosis.
2. Umbilical Cord Quantitative Polymerase Chain Reaction and Sepsis Complications for Neonates.
In this prognostic study of 15,290 very-low-birth-weight infants from 67 neonatal intensive care units, umbilical-cord qPCR detected bacterial DNA in 3.6% compared with 0.6% positive blood cultures. For sepsis-related mortality, qPCR sensitivity was 41.2% versus 23.5% for blood culture, and for grade IV intraventricular hemorrhage it was 8.2% versus 1.6%; positive qPCR remained independently associated with both outcomes.
Impact: This large multicenter study challenges the assumption that blood culture adequately captures early-onset neonatal sepsis burden. The substantial increase in detection of infants at risk for fatal sepsis or severe intraventricular hemorrhage could influence neonatal risk stratification and future diagnostic algorithms.
Clinical Implications: Umbilical-cord qPCR may complement blood culture for identifying high-risk preterm infants, particularly when blood volume is limited or culture sensitivity is low. It should not yet be used alone to diagnose infection or trigger antibiotics because positive molecular detection may reflect bacterial DNA without proving viable infection.
Key Findings
- Among 15,290 preterm infants, blood culture was positive in 0.6%, whereas umbilical-cord qPCR was positive in 3.6%.
- For sepsis-related mortality, qPCR sensitivity was 41.2% compared with 23.5% for blood culture.
- For grade IV intraventricular hemorrhage, qPCR sensitivity was 8.2% compared with 1.6% for blood culture.
- Positive umbilical-cord qPCR was associated with sepsis-related mortality after adjustment, with an odds ratio of 14.90.
Methodological Strengths
- The study included a large cohort from 67 level 3 neonatal intensive care units.
- It directly compared molecular detection with blood culture and adjusted associations for known clinical risk factors.
Limitations
- The observational prognostic design cannot establish that qPCR-positive results represent viable infection or a causal pathway to adverse outcomes.
- qPCR targeted Enterobacteriaceae and group B Streptococcus, so pathogens outside these targets may have been missed.
Future Directions: Prospective studies should determine whether qPCR-guided risk stratification improves antibiotic stewardship and outcomes, define pathogen-specific and quantitative thresholds, and evaluate cost, turnaround time, contamination risk, and integration with clinical criteria.
IMPORTANCE: Sepsis occurring in the first 72 hours of life is associated with high mortality and complications such as intraventricular hemorrhage (IVH), particularly in preterm infants. Although blood culture is the diagnostic standard, its low detection rate may underestimate the clinical burden of infection. OBJECTIVE: To determine whether molecular detection of bacterial DNA in umbilical cord tissue improves identification of preterm infants at risk of sepsis-related death or grade IV IVH. DESIGN, SETTING, AND PARTICIPANTS: Samples were collected from infants with a birth weight less than 1500 g between January 2009 and December 2021 in a research network of level 3 neonatal intensive care units (67 sites).
3. Continuous vs intermittent meropenem administration in critically ill patients and renal function. A secondary post-hoc analysis of the MERCY trial.
This secondary analysis of the multicenter MERCY randomized trial evaluated 586 critically ill patients across 31 ICUs in four countries, stratified by estimated glomerular filtration rate. Continuous meropenem infusion did not improve the composite outcome of 28-day mortality or emergence of pandrug/extensively drug-resistant pathogens compared with intermittent administration in any renal-function subgroup, while lower eGFR was associated with reduced emergence of these resistant pathogens.
Impact: The study provides clinically relevant negative evidence against assuming that continuous meropenem infusion is universally superior in critically ill patients with altered renal function. It supports individualized dosing decisions rather than routine preference for one administration strategy and highlights the complex relationship between renal clearance and antimicrobial resistance emergence.
Clinical Implications: Routine conversion from intermittent to continuous meropenem infusion cannot be recommended solely on the basis of renal-function subgroup. Clinicians should continue to use therapeutic drug monitoring when available and tailor dosing to renal function, pathogen susceptibility, infection site, illness severity, and local resistance patterns.
Key Findings
- The analysis included 586 MERCY participants with available estimated glomerular filtration rate from 31 ICUs in four countries.
- Continuous meropenem infusion provided no benefit over intermittent boluses for the composite outcome in any renal-function subgroup.
- Lower estimated glomerular filtration rate was associated with reduced emergence of pandrug- or extensively drug-resistant pathogens.
- The findings argue against using continuous infusion as a universal strategy for critically ill septic patients.
Methodological Strengths
- The analysis was based on a multicenter randomized controlled trial conducted in 31 ICUs across four countries.
- Renal-function subgroup analyses addressed a clinically relevant effect modifier for meropenem pharmacokinetics and treatment response.
Limitations
- This was a secondary post-hoc analysis and may have limited power for interaction testing within renal-function subgroups.
- The results may not generalize to dosing regimens, pathogens, therapeutic drug-monitoring protocols, or patient populations outside the MERCY trial.
Future Directions: Future trials should evaluate pharmacokinetically guided meropenem dosing, therapeutic drug monitoring, dynamic renal-function changes, augmented renal clearance, and pathogen-specific targets. Analyses should also examine whether selected subgroups with difficult-to-treat infections benefit from continuous infusion.
OBJECTIVE: In septic patients renal function changes are common, potentially affecting antibiotic therapies. Time-dependent antibiotics, administered as continuous infusion, can improve the time above the minimal inhibitory concentration, but the relationship between meropenem administration strategy and renal function remains unclear. This study aimed to investigate such relationship for a composite primary outcome of 28-day mortality and emergence of pandrug (PDR) or extensively drug-resistant (XDR) pathogens. Secondary aims were to investigate the impact of renal function on clinical and microbiological outcomes, regardless of meropenem administration strategy. DESIGN: Secondary analysis of the MERCY randomized controlled trial (Continuous Infusion versus Intermittent Administration of MERopenem in CriticallY Ill Patients). SETTING: Thirty-one ICUs in 4 countries.